Merck's OncoImmune COVID-19 Therapeutic Stuck at Starting Gate Pending Further Data

Merck will have to wait to see if a COVID-19 therapeutic gained in November through the $425 million acquisition of OncoImmune can receive Emergency Use Authorization (EUA). On Thursday, the company said the U.S. Food and Drug Administration wants to see additional data beyond the Phase III study announced last year.